You are here:

safinamide (Xadago)

Advice

in the absence of a submission from the holder of the marketing authorisation:

safinamide (Xadago®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: safinamide (Xadago)
SMC Drug ID: 1259/17
Manufacturer: Zambon SpA
Indication: for the treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to-late stage fluctuating patients.
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 June 2017

Back